Figure 6.

The fate of the GFP⁺/BrdU⁺ cells is altered by brain ischemia. (a) Representative images of GFP (green), BrdU (white) and NG2 (red) immunofluorescence in contralateral and ipsilateral dorsal cortex of mice 72 h and 8 weeks after MCAo. Arrows (yellow) show GFP⁺/BrdU⁺ cells positive for NG2 whereas head arrows (blue) show GFP⁺/BrdU⁺ cells negative for NG2. Scale bar=20 μm. (b) Stacked bar graphs show the quantitative analysis of percentages of NG2⁺ and NG2⁻ cells within the GFP⁺/BrdU⁺ cell population in contralateral and ipsilateral ROIs (n=3 mice for 1 week and 8 weeks; n=4 mice for 72 h and 2 weeks) in the contralateral (upper graphs) and ipsilateral (lower graphs) side. NG2⁺ cells in contralateral ventral cortex: 8w versus 72 h *P<0.05; NG2⁺ cells in ipsilateral ventral cortex and corpus callosum: 8 weeks versus 72 h *P<0.05; NG2⁻ cells in ipsilateral corpus callosum and striatum: 8 weeks versus 72 h *P<0.05; one-way ANOVA followed by Bonferroni post-hoc analysis. NG2⁺ and NG2⁻ cells in ipsilateral striatum: *P<0.05; one-way ANOVA